Atrial Fibrillation (AF) is the most common type of arrhythmia that causes an irregular and often fast heart rhythm. Over the past two decades, an increasing prevalence of atrial fibrillation cases is seen across the globe. According to American Heart Association, around 33.5 million people were suffering from atrial fibrillation around the world in 2013. Furthermore, about 200,000 to 400,000 new atrial fibrillation cases are diagnosed each year in the U.S.

The global AF surgery product market was worth $791.5 Million in 2014 and is estimated to reach $1.73 Billion by 2020. This market is segmented on the basis of surgical procedures into catheter ablation and surgical ablation. Catheter and surgical ablation procedures are well accepted for the treatment of atrial fibrillation. Catheter ablation holds a larger market share and is poised to grow at a CAGR of 14.5% during the forecast period.

North America was the largest contributor (in terms of monetary value) in atrial fibrillation surgery market in 2014 and will continue to dominate this market by 2020. However, Asia-Pacific is expected to be the fastest growing market for the forecast period. Regulatory policies in Asia-Pacific countries are more adaptive and business-friendly, due to the presence of less-stringent regulations and data requirements. Additionally, increasing competition in mature markets will compel atrial fibrillation catheter ablation device manufacturers to focus on emerging markets in the coming years.

The increasing number of people suffering from atrial fibrillation is the major driving force for this market. Favorable regulations are supporting the increasing use of catheter and surgical ablation treatments for AF. Larger prevalence of atrial fibrillation and lower treatment cost would support the increasing number of atrial fibrillation surgical and catheter ablation procedures in countries like France.

The major players in the Atrial Fibrillation Surgery Market include Biosense Webster, Inc., St. Jude Medical, Inc., Medtronic, Inc., Boston Scientific Corporation, Articure, Inc., Cardiofocus, Inc., nContact, Inc., Cardima, Inc. and Biotronik SE & Co.

Atrial Fibrillation Surgery Market : Scope of the Report

This report talks about the following segments in this market:

Atrial Fibrillation Surgery Market, by Product

Catheter Ablation

Surgical Ablation

Atrial Fibrillation Surgery Procedures

Catheter Ablation

Surgical Ablation

Atrial Fibrillation Surgery Market, by Geography

North America U.S. Canada

Europe Germany France U.K. RoE

Asia-Pacific Japan China India RoAP

Rest of the World

Atrial fibrillation (AF) is the most common type of arrhythmia that causes an irregular and often fast heart rhythm. Increasing prevalence of atrial fibrillation has been observed across the globe. According to American Heart Association, about 200,000 to 400,000 new atrial fibrillation cases are diagnosed each year in the U.S. The major factor driving this market is the increasing number of people suffering from atrial fibrillation. Favorable regulatory scenario would also propel growth in this market.

On the basis of surgical procedures this market is segmented into catheter ablation and surgical ablation. Catheter ablation procedures hold the major share in this market and are expected to grow with the highest CAGR during the forecast period of 2015 to 2020. Nevertheless, surgical ablation market is also expected to have a growth rate close to catheter ablation during the forecast period. The development in the surgical ablation technology and better results of these procedures are driving the overall number of surgical ablation procedures.

On the basis of geography, this market is segmented into: North America, Europe, Asia-Pacific and RoW. North America held the largest share in this market in 2014 and is expected to grow with the highest CAGR, including the number of procedures and revenue. On the other hand, Asia-Pacific is expected to be the fastest growing region due to the presence of a large patient population, growing medical tourism, and high focus of global market players on emerging Asia-Pacific countries such as China and India.

The major players in this market include Biosense Webster, Inc., St. Jude Medical, Inc., Medtronic, Inc., Boston Scientific Corporation, Articure, Inc., Cardiofocus, Inc., nContact, Inc., Cardima, Inc. and Biotronik SE & Co. As of 2014, the atrial fibrillation catheter ablation market was highly consolidated with top 4 companies dominating the entire market. The market was dominated by Biosense Webster, Inc., a J&J company (U.S.), St. Jude Medical, Inc. (U.S.), Medtronic, Inc. (U.S.), and Boston Scientific Corporation (U.S.).